NPM1 mutations, one of the most common genetic drivers of AML, are now actionable for patients –– Acute unmet need in R/R ...
NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- BitMart US , a leading crypto exchange, today announced the official launch of its U.S. platform, marking a significant milestone in the company’s expansion ...
INQUIRER.net USA on MSN
Alkagesta Singapore: Building a trusted bridge between Europe and Asia
Why did Alkagesta choose Singapore and Malta? At first glance, it seems to be a question of geography. In reality, the ...
Cotribute, a leading digital growth platform for credit unions, announced today Heritage South Community Credit Union (Heritage South) has launched its consumer account opening and consumer loan ...
IR uses the blood vessel network in the body as almost like a subway map. We can get on and off at different stops to access different parts of the body and treat disease. IR is the intersection of ...
Plans to develop 135 homes in a Suffolk market town have received 141 objections with many concerned about flooding and an increase in traffic. Framlingham Town Council is also set to object to ...
We led major clinical trials in radiotherapy and imaging which have changed standard clinical practice for cancer treatment.
Flashpoint Therapeutics, a biotechnology company pioneering a new class of structural nanomedicine, announced today the publication of foundational research demonstrating the power of its proprietary ...
SymphonyAI, a global leader in vertical AI product platforms, and AML Intelligence, the leading source of news and insight for the financial crime compliance community, today released the FinCrime ...
To help with this transition, DCI has named long-time partner RiskScout as its preferred BSA/AML and Fraud vendor to bring advanced financial crime solutions to users. RiskScout, a financial ...
Fintech law company Gofaizen & Sherle has announced the launch of the Crypto License Navigator, an interactive tool designed ...
BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback